Join the club for FREE to access the whole archive and other member benefits.

New research with senolytics shows promising results

Senolytic research is in its nascent stage but no reason why one shouldn't be hopeful


Key points from article :

Concerns have been with dasatinib plus quercetin(DQ) as a senolytic therapy but recent study shows positive results.

Senolytics target senescent cells – cells that have reached their division limit, but persist and produce toxic chemicals.

They reduce tissue repair, contribute to chronic inflammation, neurodegeneration, cancer and other age-related diseases.

Researchers showed that a 3-day course of DQ selectively eliminated senescent cells in 9 people aged 55-79.

Positive results were seen in patients with diabetic chronic kidney disease, idiopathic pulmonary fibrosis and human skin biopsies with systemic sclerosis.

“The demonstration that senescent cell numbers can be reduced in two tissues in humans is an important advance based on the compelling evidence from studies in laboratory mice"-Ronald Kohanski, NIA

Research by Mayo Clinic published in EbioMedicine.

Mentioned in this article:

Click on resource name for more details.


Medical journal covering all fields in the biomedical research

Mayo Clinic

Non-profit American academic medical center focused on health care, education, and research

National Institute on Aging (NIA)

Conducting and supporting research on aging and the health and well-being of older people.

Ronald Kohanski

Deputy Director of the Division of Aging Biology at the National Institute on Aging.

Topics mentioned on this page:
Senescent Cells